<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249037</url>
  </required_header>
  <id_info>
    <org_study_id>19-0829</org_study_id>
    <nct_id>NCT04249037</nct_id>
  </id_info>
  <brief_title>Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV</brief_title>
  <acronym>B-HASTE</acronym>
  <official_title>Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn about whether starting HIV treatment very soon after diagnosis is
      more beneficial than waiting until entering routine clinical care after diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized two arm, multi-site (three sites), open label pilot study conducted with
      laboratory evaluation and visits at entry, 4 weeks, 12 weeks, 24 weeks, 48 weeks and 96 weeks
      with laboratory evaluations and assessment if participants remain engaged in care.

      Participants will be randomly assigned with equal probability to one of two arms:

      Arm A: Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir
      alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work
      referral.

      Arm B: Standard initiation of ART at the discretion of provider + new diagnosis package with
      laboratory evaluations and social work referral.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Suppression</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of participants with viral suppression to &lt;50 copies/mL at 48 weeks by FDA snapshot in the rapid-start ART arm compared to the standard of care arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Arm A: Rapid Start Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Standard Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)</intervention_name>
    <description>A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.</description>
    <arm_group_label>Arm A: Rapid Start Group</arm_group_label>
    <other_name>Biktarvy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard initiation of antiretroviral therapy (ART)</intervention_name>
    <description>Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.</description>
    <arm_group_label>Arm B: Standard Group</arm_group_label>
    <other_name>Standard of Care ART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 15 years and older in Colorado and 19 years and older in Nebraska. A
             waiver of parental consent is planned for individuals 15-17 in accordance with
             Colorado law which allows minors to consent for treatment for sexually transmitted
             infections, including HIV.

          -  Reactive HIV-1 on an approved fourth generation HIV-1 antibody/antigen test within 72
             hours

          -  Any primary language with access to an interpreter by phone is included.

        Exclusion Criteria:

          -  Pregnancy or intention to become pregnant in the next two years after enrollment

          -  Symptomatic acute HIV (with fever, rash, influenza-like symptoms)

          -  Creatinine clearance &lt;30 mL/min by Cockcroft-Gault equation. (Therapy initiated will
             be terminated promptly in individuals who are found to have creatinine clearance &lt;30
             mL/min)

          -  Prior history of known HIV diagnosis

          -  Negative confirmatory HIV differentiation assays (therapy initiated will be terminated
             in individuals with negative tests and excluded from the primary analysis)

          -  Allergy to bictegravir, emtricitabine or tenofovir alafenamide

          -  Signs or symptoms of opportunistic infection with cryptococcal meningitis,
             tuberculosis or other infection that requires delay of initiation of antiretroviral
             therapy (up to the discretion of the site PI)

          -  Vulnerable populations including prisoners and individuals without decision making
             capacity

          -  Concommitant use of medications that are contraindicated with bictegravir,
             emtricitabine and tenofovir alafenamide including adefovir, carbamazepine, cladribine,
             dofetilide, fosphenytoin-phenytoin, oxcarbazepine, phenobarbital, primidone, rifampin,
             rifabutin, rifapentine, St. John's Wort, tipranavir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillary Dunlevy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hillary Dunlevy, MD</last_name>
    <phone>303-724-9307</phone>
    <email>hillary.dunlevy@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Fiorillo, MSPH</last_name>
    <phone>303-724-5931</phone>
    <email>suzanne.fiorillo@cuanschutz.edu</email>
  </overall_contact_backup>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

